Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T, Kobashigawa T, Tokunaga K, Tsuchiya N, Kamatani N, Kotake S
Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan.
Clin Exp Rheumatol. 2007 Mar-Apr;25(2):219-24.
To evaluate the role of HLA-DRB1 genotypes and antibodies to cyclic citrullinated peptides (anti-CCP antibodies) in the development and radiographic progression of Japanese patients with rheumatoid arthritis (RA).
One hundred and ten patients with early RA (88 female, 22 male) who visited our clinic within 1 year of symptom onset were examined for anti-CCP antibody levels and HLA-DRB1 genotypes. HLA-DRB1 genotypes were also determined in 265 healthy controls. Radiographic progression over a 2-year interval was evaluated using the Larsen's method in 66 patients.
Among the 110 patients with early RA, 82 patients (74.5%) were anti-CCP positive. Carrier frequency of HLA-DRB10405 was significantly increased in RA patients with anti-CCP antibodies compared with controls and RA patients without anti-CCP antibodies (odds ratio [OR] 3.4, 95% confidence interval [95% CI] 2.0-5.7 and OR 3.3, 95% CI 1.3-8.6, respectively). Carriership of one or two SE alleles was significantly associated with production of anti-CCP antibodies (OR 2.7, 95% CI 1.1-6.7 and OR 9.3, 95% CI 1.1-78.2, respectively). On the other hand, allele frequency of HLA-DRB10901 was significantly increased in RA patients without anti-CCP antibodies compared with controls and RA patients with anti-CCP antibodies (OR 2.2, 95% CI 1.1-4.1 and OR 3.0, 95% CI 1.4-6.4, respectively).
In Japanese patients with RA, HLA-DRB1 SE alleles are associated with production of anti-CCP antibodies and HLA-DRB1 alleles appear to be differently associated with early RA depending on anti-CCP positivity as in Caucasian patients with RA.
评估HLA - DRB1基因型和抗环瓜氨酸肽抗体(抗CCP抗体)在日本类风湿关节炎(RA)患者病情发展及影像学进展中的作用。
对110例症状出现1年内就诊于我院的早期RA患者(88例女性,22例男性)检测抗CCP抗体水平及HLA - DRB1基因型。同时对265名健康对照者也进行HLA - DRB1基因型测定。采用Larsen法对66例患者2年间的影像学进展进行评估。
110例早期RA患者中,82例(74.5%)抗CCP抗体阳性。与对照组及抗CCP抗体阴性的RA患者相比,抗CCP抗体阳性的RA患者中HLA - DRB10405的携带频率显著增加(优势比[OR]分别为3.4,95%置信区间[95%CI]为2.0 - 5.7和OR 3.3,95%CI为1.3 - 8.6)。携带一个或两个SE等位基因与抗CCP抗体的产生显著相关(OR分别为2.7,95%CI为1.1 - 6.7和OR 9.3,95%CI为1.1 - 78.2)。另一方面,与对照组及抗CCP抗体阳性的RA患者相比,抗CCP抗体阴性的RA患者中HLA - DRB10901的等位基因频率显著增加(OR分别为2.2,95%CI为1.1 - 4.1和OR 3.0,95%CI为1.4 - 6.4)。
在日本RA患者中,HLA - DRB1 SE等位基因与抗CCP抗体的产生相关,并且与白种人RA患者一样,HLA - DRB1等位基因似乎根据抗CCP抗体阳性情况与早期RA有不同的关联。